BASELINE INTERLEUKIN-17A PREDICT TREATMENT RESPONSE TO TOCILIZUMAB AND DISEASE-MODIFYING ANTIRHEUMATIC DRUGS THERAPY

被引：0

作者：

Lee, S. J. ^{[1
,2
,3
]}

Yoon, M. J. ^{[3
]}

Joo, S. H. ^{[3
]}

Park, W. ^{[4
]}

Park, S. H. ^{[5
]}

Shim, S. C. ^{[6
]}

Baek, H. J. ^{[7
]}

Yoo, D. -H. ^{[8
]}

Kim, H. A. ^{[9
]}

Lee, S. K. ^{[10
]}

Lee, Y. J. ^{[11
]}

Park, Y. E. ^{[12
]}

Cha, H. -S. ^{[13
]}

Choi, I. A. ^{[14
]}

Lee, E. Y. ^{[1
,2
]}

Lee, E. B. ^{[1
,2
]}

Song, Y. W. ^{[1
,2
,3
]}

机构：

[1] Seoul Natl Univ, WCU, Grad Sch Convergence Sci & Technol, Seoul, South Korea

[2] Seoul Natl Univ, Coll Med, Med Res Inst, Seoul, South Korea

[3] Seoul Natl Univ Hosp, Div Rheumatol, Seoul 110744, South Korea

[4] Inha Univ Hosp, Div Rheumatol, Seoul, South Korea

[5] Catholic Univ Korea, Seoul St Marys Hosp, Div Rheumatol, Seoul, South Korea

[6] Eulji Univ Hosp, Div Rheumatol, Taejon, South Korea

[7] Gachon Univ, Gil Med Ctr, Div Rheumatol, Inchon, South Korea

[8] Hanyang Univ, Med Ctr, Div Rheumatol, Seoul 133791, South Korea

[9] Hallym Univ, Med Ctr, Div Rheumatol, Seoul, South Korea

[10] Yonsei Univ Hlth Syst, Div Rheumatol, Seoul, South Korea

[11] Seoul Natl Univ, Bundang Hosp, Div Rheumatol, Seoul, South Korea

[12] Pusan Natl Univ Hosp, Div Rheumatol, Pusan, South Korea

[13] Sam Sung Med Ctr, Div Rheumatol, Seoul, South Korea

[14] Chung Buk Natl Univ Hosp, Div Rheumatol, Cheongju, South Korea

来源：

ANNALS OF THE RHEUMATIC DISEASES | 2014年 / 73卷

关键词：

D O I：

10.1136/annrheumdis-2014-eular.5095

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

SAT0059

引用

页码：610 / 611

页数：2

共 50 条

[31] Machine Learning Prediction of Treatment Response to Biological Disease-Modifying Antirheumatic Drugs in Rheumatoid Arthritis
Salehi, Fatemeh
Lopera Gonzalez, Luis I.
Bayat, Sara
Kleyer, Arnd
Zanca, Dario
Brost, Alexander
Schett, Georg
Eskofier, Bjoern M.
JOURNAL OF CLINICAL MEDICINE, 2024, 13 (13)
[32] DISEASE-MODIFYING ANTIRHEUMATIC DRUG-THERAPY - AN EXPENSIVE THERAPY DESPITE INEXPENSIVE DRUGS
BORG, G
ALLANDER, E
GOOBAR, JE
SCANDINAVIAN JOURNAL OF RHEUMATOLOGY, 1990, 19 (02) : 115 - 121
[33] A clinical and economic review of disease-modifying antirheumatic drugs
Gabriel, SE
Coyle, D
Moreland, LW
PHARMACOECONOMICS, 2001, 19 (07) : 715 - 728
[34] Conventional disease-modifying antirheumatic drugs in early arthritis
Sokka, T
Hannonen, P
Möttönen, T
RHEUMATIC DISEASE CLINICS OF NORTH AMERICA, 2005, 31 (04) : 729 - +
[35] Putting new disease-modifying antirheumatic drugs into perspective
Saseen, Joseph J.
PHARMACOTHERAPY, 2007, 27 (12): : 1609 - 1610
[36] Perinatal Use and Discontinuation of Disease-Modifying Antirheumatic Drugs
Rebic, Nevena
De Vera, Mary A.
Gupta, Amit
Amiri, Neda
JCR-JOURNAL OF CLINICAL RHEUMATOLOGY, 2024, 30 (05) : 188 - 192
[37] Targeted synthetic disease-modifying antirheumatic drugs in spondyloarthritis
Wendling, Daniel
Prati, Clement
IMMUNOTHERAPY, 2017, 9 (03) : 221 - 223
[38] Disease-modifying antirheumatic drugs: enhancing efficacy by combination
Schnabel, A
LANCET, 2004, 363 (9410): : 670 - 671
[39] Proposal for a new nomenclature of disease-modifying antirheumatic drugs
Smolen, Josef S.
van der Heijde, Desiree
Machold, Klaus P.
Aletaha, Daniel
Landewe, Robert
ANNALS OF THE RHEUMATIC DISEASES, 2014, 73 (01) : 3 - 5
[40] Safety overview of new disease-modifying antirheumatic drugs
Cush, JJ
RHEUMATIC DISEASE CLINICS OF NORTH AMERICA, 2004, 30 (02) : 237 - +

← 1 2 3 4 5 →